CytoSorbents Corporation reported its Q1 2026 earnings, revealing a larger-than-expected loss with an EPS of -$0.05 compared to the forecasted -$0.04. Revenue also fell short at $8.9 million against a $9.23 million forecast.
The stock reacted negatively, dropping 7.53% in after-hours trading and continuing to decline by 3.82% in subsequent trading sessions, nearing its 52-week low.
Despite the miss, the company highlighted progress in cost reduction, with operating expenses down 8.9% year-over-year. Management aims to achieve operating cash flow breakeven in the second half of 2026.
Revenue forecasts for FY2026 and FY2027 show modest growth, with anticipated revenues of $39.28 million and $49.08 million, respectively.
